Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial
Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses becaus...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-11-01
|
| Series: | Italian Journal of Medicine |
| Subjects: | |
| Online Access: | https://italjmed.org/index.php/ijm/article/view/1533 |
| _version_ | 1797423257992822784 |
|---|---|
| author | Yasir Mehmood Hira Shahid Aysha Tariq Syeda Omama Ali |
| author_facet | Yasir Mehmood Hira Shahid Aysha Tariq Syeda Omama Ali |
| author_sort | Yasir Mehmood |
| collection | DOAJ |
| description |
Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects’ congestion as determined by the physicians’ assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children.
|
| first_indexed | 2024-03-09T07:43:52Z |
| format | Article |
| id | doaj.art-ee59e46330c04be38f4553bc3e15420e |
| institution | Directory Open Access Journal |
| issn | 1877-9344 1877-9352 |
| language | English |
| last_indexed | 2024-03-09T07:43:52Z |
| publishDate | 2022-11-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Italian Journal of Medicine |
| spelling | doaj.art-ee59e46330c04be38f4553bc3e15420e2023-12-03T04:13:27ZengPAGEPress PublicationsItalian Journal of Medicine1877-93441877-93522022-11-0116110.4081/itjm.2022.1533Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trialYasir Mehmood0Hira Shahid1Aysha Tariq2Syeda Omama Ali3Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad, Pakistan; Saffron Pharmaceuticals (Pvt.) Ltd, FaisalabadSaffron Pharmaceuticals (Pvt.) Ltd, Faisalabad, Pakistan; Department of Pharmacology, Faculty of Pharmaceutical Sciences, GC University Faisalabad, FaisalabadFaculty of Pharmacy, University of LahoreQuaid-e- Azam Medical College, Bahawalpur Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects’ congestion as determined by the physicians’ assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children. https://italjmed.org/index.php/ijm/article/view/1533Acute rhinosinusitismometasone furoate nanonasal sprayrandomized controlled trialeffectiveness and safety. |
| spellingShingle | Yasir Mehmood Hira Shahid Aysha Tariq Syeda Omama Ali Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial Italian Journal of Medicine Acute rhinosinusitis mometasone furoate nanonasal spray randomized controlled trial effectiveness and safety. |
| title | Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial |
| title_full | Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial |
| title_fullStr | Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial |
| title_full_unstemmed | Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial |
| title_short | Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial |
| title_sort | efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis a randomized clinical trial |
| topic | Acute rhinosinusitis mometasone furoate nanonasal spray randomized controlled trial effectiveness and safety. |
| url | https://italjmed.org/index.php/ijm/article/view/1533 |
| work_keys_str_mv | AT yasirmehmood efficacyandsafetyofanewmometasonefuroatenasalsprayformulationinpatientswithacuterhinosinusitisarandomizedclinicaltrial AT hirashahid efficacyandsafetyofanewmometasonefuroatenasalsprayformulationinpatientswithacuterhinosinusitisarandomizedclinicaltrial AT ayshatariq efficacyandsafetyofanewmometasonefuroatenasalsprayformulationinpatientswithacuterhinosinusitisarandomizedclinicaltrial AT syedaomamaali efficacyandsafetyofanewmometasonefuroatenasalsprayformulationinpatientswithacuterhinosinusitisarandomizedclinicaltrial |